Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (226)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (639)
  2. Solid Tumor Oncology Division (639)
  3. Thoracic Oncology (639)
  4. Department of Pathology and Laboratory Medicine (210)
  5. GSK Faculty (191)
  6. Hematology-Oncology Fellows (186)

More Groups

People
  1. Marc Ladanyi (123)
  2. Mark Kris (91)
  3. Maria Arcila (83)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (23)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (85)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (119)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
    Meeting Abstract

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R. S.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update
    Meeting Abstract

    Ahn, M. J.; Cho, B.; Kim, T. M.; Han, J. Y.; Kim, C.; Shim, B.; Drilon, A.; Blumenschein, G.; Villaruz, L.; Gray, J. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; PeĢrol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Spano, J. P.; Nilsson, A.; Deyell, R. J.; Doz, F.; Geoerger, B.; Gumus, M.; Lassen, U. N.; Nysom, K.; Valero-Arrese, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Comprehensive pan-cancer analysis of oncogenic MET rearrangements with a focus on targetability in NSCLC
    Meeting Abstract

    Vojnic, M.; Febres-Aldana, C. A.; Odintsov, I.; Zhang, T.; Beach, C. Z.; Lu, D.; Mattar, M. S.; Gazzo, A.; Gili, L.; Harshan, M.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy, safety, and biomarker analysis in patients with TRK fusion lung cancer treated with larotrectinib
    Meeting Abstract

    Lin, J. J.; Tan, D. S. W.; Kummar, S.; Moreno, V.; Leyvraz, S.; Dubashi, B.; Parambath, H.; Burcoveanu, D. I.; Neu, N.; Leserer, S.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • OncoKB: Automated somatic variant classification for rapid clinical decision making
    Meeting Abstract

    Suehnholz, S.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Cavender, K.; Preiser, B.; Konecny, J.; more...
    Journal of Molecular Diagnostics (2024)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers
    Meeting Abstract

    Subbiah, V.; Drilon, A.; Bestvina, C.; Garon, E. B.; Wirth, L.; Worden, F.; Piha-Paul, S.; Rotow, J.; Johnson, M.; Kang, H.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save